CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 89 enrolled
Drug / intervention
acupuncture +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04182295
NCT04182295N/ACompleted

Effect of Information on Placebo in the Informed Consent on the Trial Outcomes and Participant Blinding

Kyunghee University·interventional·Posted Dec 2, 2019·Updated Sep 2, 2020

In Brief

A clinical study evaluating acupuncture and Park Sham Needle for Muscle Soreness. Completed, enrolled 89 participants across 1 site.

Detailed Summary

This is a randomised sham-controlled trial involving healthy volunteers to determine the effect of information on placebo, i.e., sham acupuncture, given in the informed consent, on the trial outcomes and blinding status of participants in a trial.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMuscle Soreness
CountriesSouth Korea

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedDec 2, 2019
Enrollment StartOct 7, 2019
Primary CompletionDec 20, 2019
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 6.6 years ago

Interventions

acupuncturedevice

A sterilised stainless steel needle (diameter 0.25mm X length 40mm, Dongbang Acupuncture Inc., Boryeong, Chungchenongnam-do, Korea) will be given at PC3, LI4, LI11, and LU5 of non-dominant arm for 15 minutes once a day for 3 days (immediately after inducing delayed onset muscle soreness (DOMS), and 2 consecutive days after inducing DOMS).

Park Sham Needledevice

A Park Sham Needle (Meridius Medical Ltd. \& DongBang Acuprime Ltd., Exeter, UK), non-penetrating sham acupuncture, will be given at two points on the belly of biceps brachii, 1 cun proximedially from LI11, and 1 cun laterally from PC3 of non-dominant arm for 15 minutes once a day for 3 days (immediately after inducing delayed onset muscle soreness (DOMS), and 2 consecutive days after inducing DOMS).